{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:27:15Z","timestamp":1793852835483,"version":"4.6.1"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jclinepi.2026.112479","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:39:31Z","timestamp":1787701171000},"page":"112479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["reFLASH: a proof-of-concept meta-analytic framework to validate surrogate endpoints in the absence of randomized clinical trial data"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5695-911X","authenticated-orcid":false,"given":"C.","family":"Bommier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6612-1564","authenticated-orcid":false,"given":"J.G.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"J.R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jclinepi.2026.112479_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostat Oxf Engl"},{"issue":"2","key":"10.1016\/j.jclinepi.2026.112479_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s10147-009-0885-4","article-title":"Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials","volume":"14","author":"Shi","year":"2009","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jclinepi.2026.112479_bib4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jclinepi.2026.112479_bib5","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2018.77.9124","article-title":"Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-Cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL)","volume":"36","author":"Shi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jclinepi.2026.112479_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood.2023020984","article-title":"Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy","volume":"143","author":"Bommier","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jclinepi.2026.112479_bib7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials","volume":"43","author":"Shi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jclinepi.2026.112479_bib8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.jclinepi.2026.112479_bib9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jval.2024.05.015","article-title":"A targeted review of worldwide indirect treatment comparison guidelines and best practices","volume":"27","author":"Tanaka","year":"2024","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112479_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1467-985X.2004.00293.x","article-title":"The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer","volume":"167","author":"Burzykowski","year":"2004","journal-title":"J R Stat Soc Ser A Stat Soc"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435626003550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435626003550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:04:49Z","timestamp":1793851489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435626003550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":9,"alternative-id":["S0895435626003550"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112479","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"reFLASH: a proof-of-concept meta-analytic framework to validate surrogate endpoints in the absence of randomized clinical trial data","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112479"}}